SavedAdd your journal

Journals / Yeni Tıp Dergisi / 2010 / Cilt: 27 - Sayı: 1

Relationship between sleep apnea and cardiac–metabolic diseases

Obstrüktif uyku apnesinin kardiyak ve sistemik hastalıklar ile ilişkisi

Duygu ÖZOL
Harun KARAMANLI
Pages
7–9
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The gold standard for the treatment of OSAS is continuous positive airway pressure (CPAP) and with this treatment, risk of cardiovascular diseases are reduced and control of other associated diseases are increased.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Obstructive sleep apnea syndrome (OSAS) is a disorder characterized by repetitive episodes of obstruction of airflow during sleep.
📊
Key Findings & Data:The pathophysiologic mechanisms for this relationship include nocturnal intermittent hypoxia as a result of apneas, increased sympathetic tone, oxidative stress, inflammation and endothelial dysfunction.
💡
Conclusion & Impact:The gold standard for the treatment of OSAS is continuous positive airway pressure (CPAP) and with this treatment, risk of cardiovascular diseases are reduced and control of other associated diseases are increased.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Obstructive sleep apnea syndrome (OSAS) is a disorder characterized by repetitive episodes of obstruction of airflow during sleep. It is associated with the develop-ment and progression of many cardiovascular, endocrine and neurologic pathologies such as systemic hyper-tension, insulin resistance, stroke, cardiac arrhythmias, atherosclerosis and depression. The pathophysiologic mechanisms for this relationship include nocturnal intermittent hypoxia as a result of apneas, increased sympathetic tone, oxidative stress, inflammation and endothelial dysfunction. OSAS induced hypoxia may promote the production of inflammatory cytokines. The gold standard for the treatment of OSAS is continuous positive airway pressure (CPAP) and with this treatment, risk of cardiovascular diseases are reduced and control of other associated diseases are increased.

Özet

Obstrüktif uyku apne sendromu (OSAS), uykuda tekrar-layıcı üst hava yolu daralması ile karakterize bir hasta-lıktır. Hipertansiyon, insulin direnci, felç, aritmi, atero-skleroz ve depresyonun dahil olduğu birçok kardiyo-vasküler, nörolojik, endokrinolojik hastalığın gelişme-sinde ve ilerlemesinde önemli bir rol oynamaktadır. Altta yatan patofizyolojik mekanizmalar; apne sonucu gece aralıklı gelişen hipoksemi, artmış sempatik aktivite, oksidatif stres, inflamasyon ve endotel disfonksiyonudur. OSAS sonucu gelişen hipoksi, inflamatuar sitokinlerin üretimini arttırmaktadır. OSAS için tedavide önerilen altın standart yöntem devamlı pozitif havayolu basıncı (CPAP)’dır ve bu tedavi kardiyovasküler riski azaltmakta ve diğer eşlik eden hastalıkların kontrolüne katkı sağla-maktadır.

🔖

Cite This Article

ÖZOL, D., KARAMANLI, H. (2010). Relationship between sleep apnea and cardiac–metabolic diseases. Yeni Tıp Dergisi, Cilt: 27 - Sayı: 1, 7–9. https://ajindex.com/articles/338293

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5
  2. Strohl KP, Redline S. Recognition of obstructive sleep apnea. Am J Respir Cri Care Med 1996;154: 279-89
  3. Köktürk O. Obstrüktif uyku Apne Sendromu Klinik özellikleri. Tüberküloz ve Toraks Dergisi 1999;47: 117–26
  4. Scharf SM. In: Sounder NA, Sullivan CE (editors): Influence of sleep state and breathing on cardiovasculary function. Sleep and breathing. New York:Mercel Dekker 1984: 221-29
  5. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 2004;89: 4409-13
  6. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stres disorder. Sleep Med Rev 2003;7: 35-51
  7. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med 1993;328: 303-7
  8. Lavie P, Yoffe N, Berger T, Peled R. The relationship between the severity of sleep apnea syndrome and 24-h blood pressure values in patients with obstructive sleep apnea. Chest 1993;103: 717-21
  9. Becker H, Brandenburg U, Peter JH, von Wichert P. Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. Am J Respir Crit Care Med 1995;151: 215-8
  10. Hoffstein V, Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest 1994;106: 466-71
  11. Kasasbeh E, Chi DS, Krishnaswamy G. Inflammatory aspects of sleep apnea and their cardiovascular consequences. South Med J. 2006;99: 58-67
  12. Kario K. Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. Hypertens Res 2009;32: 428-3
  13. Sullivan CE, Issa FG, Berhon-Jones M, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;1: 862-5
  14. Duchna HW, Guilleminault C, Stoohs RA, Faul JL, Moreno H, Hoffman BB, et al. Vascular reactivity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2000;161: 187-91
  15. Bounhoure JP, Galinier M, Didier A, Leophonte P. Sleep apnea syndromes and cardiovascular disease. Bull Acad Natl Med 2005;189: 445-59
  16. Cormican LJ, Williams A. Sleep disordered breathing and its treatment in congestive heart failure. Heart 2005;91: 1265-70
  17. Sin DD, Fitzgerald F, Parker JD, Newton G, F